Pensions

Givaudan SA Monitor

Givaudan SA Annual Report 2015
CR Monitor Issue: 
2016/0807
Company covered: 
Givaudan SA
Period End: 
31 December, 2015
Report issued on 23 August 2016 covered the following practice issues:
Change
Settlement of a defined benefit plan resulting in one-time gain.
Change
Enhanced disclosure of directors remuneration
Pronouncements
Probable impact of new Financial instruments standard disclosed.
Change
Provision recognised in respect of environmental obligation previously identified as a contingent liability,

FRS 101 "Reduced disclosure framework"- A review of application in parent company accounts of IFRS groups

The preparation of parent company financial statements is something that all consolidated IFRS groups have to consider. In light of the great level of recent change in this area in the UK this represents a one-off report giving guidance on the preparation of parent company financial statements under FRS 101 "Reduced Disclosure Framework". It focuses on UK groups that prepare IFRS consolidated accounts.

The report sets out the key findings from our review of the first-time application of FRS 101 “Reduced Disclosure Framework” by a group of 29 parent companies that prepare consolidated financial statements under IFRS.  We consider a number of points including: how companies informed shareholders of the intention to implement FRS 101; the format of the primary financial statements; disclosure of the list of exemptions taken; the concept of equivalent disclosure in the consolidated financial statements; the length of company financial statements under FRS 101; and changes in accounting policy on adoption. 

Pensions - AstraZeneca plc

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG

McBride plc Interims Monitor

Interim Financial Report
CR Interim Monitor Issue: 
2016/0304
Period End: 
31 December 2015
Listing Status: 
FTSE Mid 250
ICB Industry Classification: 
3724 Nondurable Household Products
Auditor: 
PricewaterhouseCoopers
Restatement
Reclassification of artwork, design and product testing costs increases cost of sales.
Change
Omission of segmental profitability.
Change
Effects of defined benefit schemes on results and financial position analysed, as benefits restricted.

Pensions - Novartis AG

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Pensions - Novartis AG

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Eni S.p.A. Interims Monitor

Interim Financial Report
CR Interim Monitor Issue: 
2015/1108
Period End: 
30 June 2015
Listing Status: 
Europe 350
ICB Industry Classification: 
0537 Integrated Oil & Gas
Auditor: 
Ernst & Young
Pronouncements
Amendment to employee benefits Standard adopted, with no significant impact.
Restatement
Segmental information restated for changes in organisation and accountability.

Electrocomponents plc Monitor

Electrocomponents plc Annual Report 2015
CR Monitor Issue: 
2015/1106
Company covered: 
Electrocomponents plc
Period End: 
31 March, 2015
Report issued on 24 November 2015 covered the following practice issues:
New
Past service gain on defined benefit pension plan increases profit before tax by 26.9%.
Change
Vendor rebates recognised on accruals basis under new guidelines.

Pensions - AstraZeneca PLC

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG